The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The purpose of this study is to determine if the administration of GSK958108 can delay ejaculation in patients with primary premature ejaculation as measured by the ejaculatory latency time (ELT) using the masturbation model and sexual visual stimulation, and to evaluate the safety and tolerability of GSK958108 in healthy men with PE
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
A Double Blind, Parallel Group, Placebo Controlled Study to Evaluate the Effect of a Single Oral Dose of GSK958108 on Ejaculatory Latency Time (ELT) in Male Patient Suffering From Premature Ejaculation
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 50 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Heterosexual male subject with self-reported moderate or severe primary Premature ejaculation with ejaculation occurring on or before penetration, or shortly there after with minimal stimulation
Baseline Ejaculation Latency time < 3 minutes
Subjects must agree to use a contraception methods as per protocol
Body weight > or = 50 kg and Body Mass Index within the range 19.0-29.9 Kg/m2
Subject with normal visual acuity (with appropriate correction if needed)
Subject able to cooperate in all study procedure including the eye examination with use of mydriatics
History of migraine
Current clinically relevant abnormality
History of psychiatric illness or suicidal attempts or behaviours
History of any eye disorder or colour blind, excluding myopia and presbyopia
Cardiac conduction disorder or other clinically significant cardiac disease
Positive at pre-study drug/alcohol screen and to Hepatitis or HIV tests
Regular consumption of alcohol
History of sensitivity or intolerance to drugs
Consumption of red wine, seville oranges, grapefruit or grapefruit juice [and/or pummelos, exotic citrus fruits, grapefruit hybrids] from 7 days prior to the first dose of study medication
Subject has received or is continuing to receive any treatment for premature ejaculation in the four weeks prior to the study start
Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements prior to the first dose of study medication
Participation in another clinical trial in the previous month
Exposure to more than four new experimental drugs within the previous 12 months
Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
Unwillingness or inability to follow the procedures outlined in the protocol.